Apolipoprotein E alleles and risk of coronary disease: A meta-analysis

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 16, Issue 10, 1996, Pages 1250-1255

  Wilson, Peter W F ^a   Schaefer, Ernst J ^c   Larson, Martin G ^b   Ordovas, Jose M ^c  

^a FRAMINGHAM HEART STUDY   (United States)

^b BOSTON UNIVERSITY   (United States)

^c TUFTS UNIVERSITY   (United States)

Author keywords

apolipoprotein E; coronary heart disease; meta analysis; molecular epidemiology

Indexed keywords

APOLIPOPROTEIN A;

ALLELE; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL ARTICLE; FEMALE; GENETIC LINKAGE; GENETIC SUSCEPTIBILITY; HUMAN; ISCHEMIC HEART DISEASE; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

EID: 0029818713     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.16.10.1250     Document Type: Article

References (42)

1. Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis. 1988;8:1-21.
2. Davignon J. Apolipoprotein E polymorphism and atherosclerosis. In: Born GVR, Schwartz CJ, eds. New Horizons in Coronary Heart Disease. London, England: Current Science; 1993:5.1-5.21.
3. Utermann G, Vogelberg KH, Steinmetz A, Schoenborn W, Pruin N, Jaeschke M, Hees M, Canzler H. Polymorphism of apolipoprotein E, II: genetics of hyperlipoproteinemia type III. Clin Genet. 1979;15:37-62.
4. Utermann G, Pruin N, Steinmetz A. Polymorphism of apolipoprotein E, III: effect of a single polymorphic gene locus on plasma lipid levels in man. clin Genet. 1979;15:63-72.
5. Eichner JE, Kuller LH, Orchard TJ, Grandits GA, McCallum LM, Ferrell RE, Neaton JD. Relation of apolipoprotein E phenotype to myocardial infarction and mortality from coronary artery disease. Am J Cardiol. 1993;71:160-165.
6. Luc G, Bard J, Arveiler D, Evans A, Cambou J, Bingham A, Amouyel P, Schaffer P, Ruidavets J, Cambien F, Fruchart J, Ducimetiere P. Impact of apolipoprotein E polymorphism on lipoproteins and risk of myocardial infarction: the ECTIM Study. Anerioscler Thromb. 1994;14:1412-1419.
7. Wilson PWF, Myers RH, Larson MG, Ordovas JM, Wolf PA, Schaefer EJ. Apolipoprotein E alleles, dyslipidemia, and coronary heart disease: the Framingham Offspring Study. JAMA. 1994;272:1666-1671.
8. Dammerman M, Breslow JL. Genetic basis of lipoprotein disorders. Circulation. 1995;91:505-512.
9. Stengard JH, Zerba KE, Pekkanen J, Ehnholm C, Nissinen A, Sing CF. Apolipoprotein E polymorphism predicts death from coronary heart disease in a longitudinal study of elderly Finnish men. Circulation. 1995;91:265-269.
10. Ordovas JM, Litwack-Klein L, Wilson PWF, Schaefer EJ. Apolipoprotein E isoform phenotyping methodology and population fre- quency with identification of Apo E1 and Apo E5 isoforms in the Framingham Offspring Study. J Lipid Res. 1987;28:371-380.
11. Hixson JE, PDAY Research Group. Apolipoprotein E polymorphisms affect atherosclerosis in young males. Arierioscler Thromb. 1991;11:1237-1244.
12. Tiret L, de Knijff P, Menzel H, Ehnholm C, Nicaud V, Havekes LM. ApoE polymorphism and predisposition to coronary heart disease in youths of different European populations: the EARS Study. Arterioscler Thromb. 1994;14:1617-1624.
13. Cumming AM, Robertson F. Polymorphism at the apo E locus in relation to risk of coronary disease. Clin Genet. 1984;25:310-313.
14. Lenzen HJ, Assmann G, Buchwalsky R, Schulte H. Association of apolipoprotein E polymorphism, low-density lipoprotein cholesterol, and coronary artery disease. Clin Chem. 1986;32:778-781.
15. Eto M, Watanabe K, Makino I. Increased frequencies of apolipoprotein e2 and e4 alleles in patients with ischemic heart disease. Clin Genet. 1989;36:183-188.
16. Yamamura T, Tajima S, Miyake Y, Nomura S, Yamamoto A, Haze K, Hiramori K. Hyperlipoproteinemia as a risk factor for ischemic heart disease. Jpn Circ J. 1990;54:448-456.
17. Eichner JE, Kuller LH, Ferrell RE, Meilahn EN, Kamboh MI. Phenotypic effects of apolipoprotein structural variation on lipid profiles, I: contribution of apolipoprotein E phenotype to prediction of total cholesterol, apolipoprotein B, and low density lipoprotein cholesterol in the Healthy Women Study. Arteriosclerosis. 1990;10:379-385.
18. Menzel H, Kladetzky R, Assmann G. Apolipoprotein E polymorphism and coronary artery disease. Arteriosclerosis. 1983;3:310-315.
19. Kuusi T, Nieminen MS, Ehnholm C, Yki-Karvinen H, Valle M, Nikkila EA, Taskinen M, Apoprotein E polymorphism and coronary artery disease: increased prevalence of apolipoprotein E-4 in angiographically verified coronary patients. Arteriosclerosis. 1989;9:237-241.
20. Stuyt PMJ, Brenninkmeijer BJ, Damacker PNM, Hendriks JCM, van Eiteren P, Stalenhoef AFH, van't Laar A. Apolipoprotein E phenotypes, serum lipoproteins and apolipoproteins in angiographically assessed coronary heart disease. Scand J Clin Lab Invest. 1991:51:425-435.
21. van Bockxmeer FM, Mamotte CD. Apolipoprotein epsilon 4 homozygosity in young men with coronary heart disease. Lancet. 1992;340:879-880.
22. Lehtinen S, Lehtimaki T, Sisto T, Salenius JP, Nikkila M, Jokela H, Koivula T, Ebeling F, Ehnholm C. Apolipoprotein E polymorphism, serum lipids, myocardial infarction and severity of angiographically verified coronary artery disease in men and women. Atherosclerosis. 1995;114:83-91.
23. Boerwinkle E, Visvikis S, Welsh D, Steinmetz J, Hanash SM, Sing CF. The use of measured genotype information in the analysis of quantitative phenotypes in man, II: the role of the apolipoprotein E polymorphism in determining levels, variability, and covariability of cholesterol, betalipoprotein, and triglycerides in a sample of unrelated individuals. Am J Med Genet. 1987;27:567-582.
24. Petitti DB. Statistical methods in meta-analysis. Meta-Analysis, Decision Analysis, and Cost-Effectiveness Analysis. New York, NY: Oxford; 1994:90-114.
25. Berlin JA, Laird NM, Sacks HS, Chalmers TC. A comparison of statistical methods for combining event rates from clinical trials. Stat Med. 1989;8:I41-151.
26. DerSimonian R, Laird NM. Meta-analysis in clinical trials. Control Clin Trials. 1994;7:177-188.
27. Breslow NE, Day NE. Classical methods of S analysis of matched data. In: Davis W, ed. Statistical Methods in Cancer Research: The Analysis of Case-Control Studies. Lyon, France: International Agency for Research on Cancer; 1980:162-189.
28. Utermann G, Hardewig A, Zimmer F. Apolipoprotein E phenotypes in patients with myocardial infarction. Hum Genet. 1984;65:237-241.
29. Wang XL, McCredie RM, Wilcken DEL. Polymorphisms of the apolipoprotein E gene and severity of coronary artery disease defined by angiography. Arterioscler Thromb Vasc Biol. 1995;15:1030-1034.
30. Castano EM, Prelli F, Wisniewski T, Golabek A, Kumar RA, Soto C, Frangione B. Fibrillogenesis in Alzheimer's disease of amyloid beta peptides and apolipoprotein E. Biochem J. 1995;306:599-604.
31. Feingold KR, Elias PM, Mao-Qiang M, Fartasch M, Zhang SH, Maeda N. Apolipoprotein E deficiency leads to cutaneous foam cell formation in mice. J Invest Dermatol. 1995;104:246-250.
32. Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 1992;258:468-471.
33. Shimano H, Yamada N, Katsuki M, Yamamoto K, Gotoda T, Harada K, Shimada M, Yazaki Y. Plasma lipoprotein metabolism in transgenie mice overexpressing apolipoprotein E: accelerated clearance of lipoproteins containing apolipoprotein B. J Clin Invest. 1992;90:2084-2091.
34. Yamada N, Shimano H, Mokuno H, Ishibashi S, Gotohda T, Kawakami M, Watanabe Y, Akanuma Y, Murase T, Takaku F. Increased clearance of plasma cholesterol after injection of apolipoprotein E into Watanabe heritable hyperlipidemic rabbits. Proc Natl Acad Sci USA. 1989;86:665-669.
35. Rader DJ, Wilson JM. Gene therapy for lipid disorders. In: Haber E, ed. Molecular Cardiovascular Medicine. New York, NY: Scientific American; 1995:97-114.
36. Boerwinkle E, Utermann G. Simultaneous effects of the apolipoprotein E polymorphism on apolipoprotein E, apolipoprotein B, and cholesterol metabolism. Am J Hum Genet. 1988;42:104-122.
37. Reilly SL, Ferrell RE, Kotlke BA, Kamboh MI, Sing CF. The genderspecific apolipoprotein E genotype influence on the distribution of lipids and apolipoproteins in the population of Rochester, MN, I: pleiotropic effects on means and variances. Am J Hum Genet. 1991;49:1155-1166.
38. Chivot L, Mainard F, Bigot E, Bard JM, Auget JL, Madec Y, Fruchart JC. Logistic discriminant analysis of lipids and apolipoproteins in a population of coronary bypass patients and the significance of apolipoproteins C-III and E. Arteriosclerosis. 1990;82:205-211.
39. Couderc R, Mahieux F, Bailleul S, Fenelon G, Mary R, Fernamian J. Prevalence of apolipoprotein E phenotypes in ischemic cerebrovascular disease: a case-control study. Stroke. 1993;24;661-664.
40. Buring JE, O'Connor GT, Goldhaber SZ, Rosner B, Herbert PN, Blum CB, Breslow JL, Hennekens CH. Decreased HDL2 and HDL3 cholesterol, apo A-I and apo A-II, and increased risk of myocardial infarction. Circulation. 1992;85:22-29.
41. Bittolo Bon G, Cazzolato G, Saccardi M, Kostner GM, Avogaro P. Total plasma apo E and high density lipoprotein E in survivors of myocardial infarction. Atherosclerosis. 1984;54:69-77.
42. Schaefer EJ, Lamon-Fava S, Johnson S, Ordovas JM, Schaefer MM, Castelli WP, Wilson PWF, Effects of gender and menopausal status on the association of apolipoprotein E phenotype with plasma lipoprotein levels: results from the Framingham Offspring Study. Arterioscler Thromb. 1994;14:1105-1113.